Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec;21(12):757-768.
doi: 10.1038/s41574-025-01157-1. Epub 2025 Aug 4.

Advances in the management of hyperglycaemia and diabetes mellitus during hospitalization

Affiliations
Review

Advances in the management of hyperglycaemia and diabetes mellitus during hospitalization

Thaer Idrees et al. Nat Rev Endocrinol. 2025 Dec.

Abstract

Diabetes mellitus, which affects over 537 million people worldwide, considerably increases the risk of emergency room visits and admissions to hospital. Inpatient hyperglycaemia in patients with or without diabetes mellitus is associated with higher rates of complications, extended hospital stays and increased mortality when compared with patients with normoglycaemia. The American Diabetes Association recommends a target range of 5.6-10.0 mmol/l (100-180 mg/dl) for levels of glucose in the blood of patients in intensive care units (ICUs), as well as in general medicine and surgery. Insulin therapy remains the cornerstone of managing inpatient hyperglycaemia, with intravenous insulin preferred in ICU and basal-bolus regimens favoured in non-ICU settings. While bedside capillary blood glucose monitoring is standard for adjusting insulin doses, continuous glucose monitoring provides a more comprehensive glycaemic assessment and enhances the prevention of hypoglycaemia in high-risk hospitalized patients. This Review outlines the latest evidence in managing diabetes mellitus and hyperglycaemia within hospitals.

PubMed Disclaimer

Conflict of interest statement

Competing interests: T.I. has received research support (paid to Emory University) from AbbVie. G.E.U. has received research support (paid to Emory University) from Bayer, Abbott, Dexcom and Corcept, and has served as a member of advisory boards for Dexcom, Mankind, Glucotrack, Corcept and GlyCare. K.K.D. has received honoraria for travel, advisory boards and speaker fees from Abbott Diabetes, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Menarini and Sanofi Diabetes. I.C.-R. and L.H. declare no competing interests.

References

    1. Umpierrez, G. E. et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 97, 16–38 (2012). - PubMed - DOI
    1. Dhatariya, K. et al. Diabetes at the front door. A guideline for dealing with glucose related emergencies at the time of acute hospital admission from the Joint British Diabetes Society (JBDS) for Inpatient Care Group. Diabet. Med. 37, 1578–1589 (2020). - PubMed - DOI
    1. American Diabetes Association Professional Practice Committee 16. Diabetes care in the hospital: standards of care in diabetes — 2025. Diabetes Care 48, S321–S334 (2024). - DOI
    1. Umpierrez, G. E. et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J. Clin. Endocrinol. Metab. 87, 978–982 (2002). - PubMed - DOI
    1. Farrokhi, F., Smiley, D. & Umpierrez, G. E. Glycemic control in non-diabetic critically ill patients. Best. Pract. Res. Clin. Endocrinol. Metab. 25, 813–824 (2011). - PubMed - PMC - DOI

LinkOut - more resources